Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Neuropsychiatr Dis Treat ; 15: 1077-1088, 2019.
Article in English | MEDLINE | ID: mdl-31118641

ABSTRACT

PURPOSE: Depression is a complex psychiatric disorder. Various depressive rodent models are usually constructed based on different pathogenesis hypotheses. MATERIALS AND METHODS: Herein, using our previously established naturally occurring depressive (NOD) model in a non-human primate (cynomolgus monkey, Macaca fascularis), we performed metabolomics analysis of cerebrospinal fluid (CSF) from NOD female macaques (N=10) and age-and gender-matched healthy controls (HCs) (N=12). Multivariate statistical analysis was used to identify the differentially expressed metabolites between the two groups. Ingenuity Pathways Analysis and MetaboAnalyst were applied for predicted pathways and biological functions analysis. RESULTS: Totally, 37 metabolites responsible for discriminating the two groups were identified. The NOD macaques were mainly characterized by perturbations of fatty acid biosynthesis, ABC transport system, and amino acid metabolism (eg, aspartate, glycine, serine, and threonine metabolism). Interestingly, we found that eight altered CSF metabolites belonging to short-chain fatty acids and amino acids were also observed in the serum of NOD macaques (N=13 per group). CONCLUSION: Our findings suggest that peripheral and central short-chain fatty acids and amino acids are implicated in the onset of depression.

2.
J Neurol Sci ; 400: 160-168, 2019 May 15.
Article in English | MEDLINE | ID: mdl-30954660

ABSTRACT

The gut microbiome is composed of an enormous number of microorganisms, generally regarded as commensal bacteria. Resident gut bacteria are an important contributor to health and significant evidence suggests that the presence of healthy and diverse gut microbiota is important for normal cognitive and emotional processing. Here we measured the expression of monoamine neurotransmitter-related genes in the hippocampus of germ-free (GF) mice and specific-pathogen-free (SPF) mice to explore the effect of gut microbiota on hippocampal monoamine functioning. In total, 19 differential expressed genes (Htr7, Htr1f, Htr3b, Drd3, Ddc, Maob, Tdo2, Fos, Creb1, Akt1, Gsk3a, Pik3ca, Pla2g5, Cyp2d22, Grk6, Ephb1, Slc18a1, Nr4a1, Gdnf) that could discriminate between the two groups were identified. Interestingly, GF mice displayed anxiolytic-like behavior compared to SPF mice, which were not reversed by colonization with gut microbiota from SPF mice. Besides, colonization of adolescent GF mice by gut microbiota was not sufficient to reverse the altered gene expression associated with their GF status. Taking these findings together, the absence of commensal microbiota during early life markedly affects hippocampal monoamine gene-regulation, which was associated with anxiolytic behaviors and monoamine neurological signs.


Subject(s)
Anxiety/genetics , Gastrointestinal Microbiome/physiology , Germ-Free Life/physiology , Hippocampus/metabolism , Neurotransmitter Agents/genetics , Neurotransmitter Agents/metabolism , Animals , Anxiety/etiology , Anxiety/psychology , Biogenic Monoamines/metabolism , Gene Regulatory Networks/physiology , Male , Mice , Mice, Inbred BALB C , Random Allocation
3.
Neuropsychiatr Dis Treat ; 14: 2461-2472, 2018.
Article in English | MEDLINE | ID: mdl-30319258

ABSTRACT

BACKGROUND: Major depressive disorder (MDD) is mediated by chronic dysregulation of complex neural circuits, particularly the specific neurotransmitters or other neural substrates. Recently, both increases and decreases in resting-state functional connectivity have been observed in patients with MDD. However, previous research has only assessed the functional connectivity within a specific network or some regions of interests, without considering the modulatory effects of the entire brain regions. To fill in the research gap, this study employed PPI (physiophysiological interaction) to investigate the functional connectivity in the entire brain regions. Apart from the traditional PPI used for cognitive research, current PPI analysis is more suitable for exploring the neural mechanism in MDD patients. Besides, this PPI method does not require a new cognitive estimation task and can assess the modulatory effects on different part of brain without prior setting of regions of interest. METHODS: First, we recruited 76 outpatients with major depressive disorder, and conducted MRI scan to acquire structural and functional images. As referred to the previous study of resting-state networks, we identified eight well-defined intrinsic resting-state networks by using independent component analysis. Subsequently, we explored the regions that exhibited synchronous modulatory interactions within the network by executing PPI analysis. RESULTS: Our findings indicated that the modulatory effects between healthy crowed and patient are different. By using PPI analysis in neuroimaging can help us to understand the mechanisms of neural disruptions in MDD patients. In addition, this study provides new insight into the complicated relationships between three or more regions of brain, as well as different brain networks functions in external and internal. CONCLUSION: Furthermore, the functional connectivity may deepen our knowledge regarding the complex brain functions in MDD patients and suggest a new multimodality treatment for MDD including targeted therapy and transcranial magnetic stimulation.

4.
Transl Psychiatry ; 8(1): 130, 2018 07 10.
Article in English | MEDLINE | ID: mdl-29991685

ABSTRACT

Major depressive disorder (MDD) is a debilitating psychiatric illness. However, there is currently no objective laboratory-based diagnostic tests for this disorder. Although, perturbations in multiple neurotransmitter systems have been implicated in MDD, the biochemical changes underlying the disorder remain unclear, and a comprehensive global evaluation of neurotransmitters in MDD has not yet been performed. Here, using a GC-MS coupled with LC-MS/MS-based targeted metabolomics approach, we simultaneously quantified the levels of 19 plasma metabolites involved in GABAergic, catecholaminergic, and serotonergic neurotransmitter systems in 50 first-episode, antidepressant drug-naïve MDD subjects and 50 healthy controls to identify potential metabolite biomarkers for MDD (training set). Moreover, an independent sample cohort comprising 49 MDD patients, 30 bipolar disorder (BD) patients and 40 healthy controls (testing set) was further used to validate diagnostic generalizability and specificity of these candidate biomarkers. Among the 19 plasma neurotransmitter metabolites examined, nine were significantly changed in MDD subjects. These metabolites were mainly involved in GABAergic, catecholaminergic and serotonergic systems. The GABAergic and catecholaminergic had better diagnostic value than serotonergic pathway. A panel of four candidate plasma metabolite biomarkers (GABA, dopamine, tyramine, kynurenine) could distinguish MDD subjects from health controls with an AUC of 0.968 and 0.953 in the training and testing set, respectively. Furthermore, this panel distinguished MDD subjects from BD subjects with high accuracy. This study is the first to globally evaluate multiple neurotransmitters in MDD plasma. The altered plasma neurotransmitter metabolite profile has potential differential diagnostic value for MDD.


Subject(s)
Depressive Disorder, Major/diagnosis , Metabolomics/methods , Neurotransmitter Agents/blood , Adult , Area Under Curve , Biomarkers/blood , Bipolar Disorder/blood , Bipolar Disorder/diagnosis , Case-Control Studies , Cohort Studies , Depressive Disorder, Major/blood , Female , Gas Chromatography-Mass Spectrometry , Humans , Logistic Models , Male , Metabolic Networks and Pathways , Middle Aged , Neurotransmitter Agents/metabolism , Sensitivity and Specificity , Severity of Illness Index
5.
Neurol Sci ; 39(1): 91-96, 2018 Jan.
Article in English | MEDLINE | ID: mdl-29052090

ABSTRACT

Parkinson's disease (PD), a progressive and age-related neurodegenerative condition, is a common neurodegenerative disorder. However, no validated biomarkers for PD have been identified to date. Accumulating evidence supports the role of proNGF-p75NTR-sortilin signaling in the neurodegeneration and pathogenesis of PD. The aim of our study was to investigate alterations in serum proNGF concentrations in PD patients and related anxiety. Seventy-seven consecutive PD patients and 39 healthy controls were enrolled, and clinical data were collected. Modified Hoehn-Yahr Staging Scale, Unified Parkinson's Disease Rating Scale (UPDRS), and Hamilton Anxiety (HAMA) Scale scores were assessed upon admission. Serum proNGF concentration was compared between that of PD patients and healthy controls. Pearson correlation coefficients were determined to explore the relationship between proNGF concentration and UPDRS, Hoehn-Yahr, and HAMA scores. Received operating characteristic (ROC) curves and proNGF optimal cutoff point were used to distinguish PD and related anxiety. The median concentration of proNGF was significantly lower (p = 0.000) in PD patients (94.91 ng/L, range 85.92-118.06 ng/L) compared with that of healthy controls (106.67 ng/L, range 102.39-122.06 ng/L). The optimal proNGF cutoff point for distinguishing PD patients was 102.29 ng/L, and the sensitivity and specificity values were 87.0 and 100%, respectively. proNGF concentration positively correlated with UPDRS (r = 0.281, p = 0.013), Hoehn-Yahr (r = 0.260, p = 0.023), and HAMA (r = 0.276, p = 0.015) scores. Our results indicate that serum proNGF concentration may represent a biomarker for PD and its role in the pathogenesis of PD thus warrants further investigation.


Subject(s)
Nerve Growth Factor/blood , Parkinson Disease/blood , Protein Precursors/blood , Anxiety/blood , Anxiety/complications , Biomarkers/blood , Female , Humans , Male , Parkinson Disease/complications , Parkinson Disease/diagnosis , Psychiatric Status Rating Scales , ROC Curve , Severity of Illness Index
6.
Neuropharmacology ; 128: 119-131, 2018 Jan.
Article in English | MEDLINE | ID: mdl-28986280

ABSTRACT

OBJECTIVES: Recombinant tissue plasminogen activator (rtPA) is widely used for patients with thromboembolic disease, and increasing evidence indicates that it can directly induce neurotoxicity independent of its thrombolysis property. Here, we aimed to confirm the long-term effect of rtPA on animal's behavior, and investigate the underlying pathogenesis. METHODS AND RESULTS: Male Sprague-Dawley rats randomly received a dose of rtPA (10 mg/kg) or sterile saline. Three months later, the animals receiving rtPA displayed anxiety-like behaviors in the open field and novelty-suppressed feeding tests. To investigate the possible pathogenesis, gas chromatography-mass spectrometry-based metabolomics analysis was performed, with 18 differential metabolites identified in the hippocampus 24 h after the treatments. Based upon these differential metabolites, a metabolite-protein integrated network was generated, which indicated that ERK1/2-glutamic acid decarboxylase (GAD) 1-γ aminobutyric acid (GABA) cascade may be related to long-term anxiety-like behaviors. The GABA levels in hippocampus were decreased 24 h post-treatment and three months later, confirmed by a high performance liquid chromatography method. We also examined the expression of GAD1 and GAD2 using western blotting or immunohistochemical staining. Levels of GAD1 were persistently decreased after treatment, while GAD2 levels, GAD1-immunoreactive, and GAD2-immunoreactive neurons showed no significant differences. The underlying pathogenesis also involved activation of ERK1/2, confirmed by increased phospho-ERK1/2 24 h post-treatment. CONCLUSIONS: RtPA can induce long-term anxiety-like behaviors after a clinical injected dose. The underlying pathogenesis involves the ERK1/2-GAD1-GABA cascade in the hippocampus. This pharmacological side effect of rtPA may further exacerbate post-stroke anxiety disorder for stroke patients.


Subject(s)
Anxiety/chemically induced , Anxiety/pathology , Hippocampus/drug effects , MAP Kinase Signaling System/drug effects , Tissue Plasminogen Activator/toxicity , Animals , Body Weight/drug effects , Disease Models, Animal , Exploratory Behavior/drug effects , Feeding Behavior/drug effects , Gene Expression Regulation/drug effects , Glutamate Decarboxylase/metabolism , Hindlimb Suspension , Hippocampus/metabolism , MAP Kinase Signaling System/physiology , Male , Maze Learning/drug effects , Metabolic Networks and Pathways/drug effects , Proto-Oncogene Proteins c-bcl-2/metabolism , Rats , Rats, Sprague-Dawley , bcl-2-Associated X Protein/metabolism , gamma-Aminobutyric Acid/metabolism
7.
PLoS One ; 11(7): e0158848, 2016.
Article in English | MEDLINE | ID: mdl-27387385

ABSTRACT

BACKGROUND AND PURPOSE: Recombinant tissue plasminogen activator (rtPA) is the only effective drug approved by US FDA to treat ischemic stroke, and it contains pleiotropic effects besides thrombolysis. We performed a meta-analysis to clarify effect of tissue plasminogen activator (tPA) on cerebral infarction besides its thrombolysis property in mechanical animal stroke. METHODS: Relevant studies were identified by two reviewers after searching online databases, including Pubmed, Embase, and ScienceDirect, from 1979 to 2016. We identified 6, 65, 17, 12, 16, 12 and 13 comparisons reporting effect of endogenous tPA on infarction volume and effects of rtPA on infarction volume, blood-brain barrier, brain edema, intracerebral hemorrhage, neurological function and mortality rate in all 47 included studies. Standardized mean differences for continuous measures and risk ratio for dichotomous measures were calculated to assess the effects of endogenous tPA and rtPA on cerebral infarction in animals. The quality of included studies was assessed using the Stroke Therapy Academic Industry Roundtable score. Subgroup analysis, meta-regression and sensitivity analysis were performed to explore sources of heterogeneity. Funnel plot, Trim and Fill method and Egger's test were obtained to detect publication bias. RESULTS: We found that both endogenous tPA and rtPA had not enlarged infarction volume, or deteriorated neurological function. However, rtPA would disrupt blood-brain barrier, aggravate brain edema, induce intracerebral hemorrhage and increase mortality rate. CONCLUSIONS: This meta-analysis reveals rtPA can lead to neurological side effects besides thrombolysis in mechanical animal stroke, which may account for clinical exacerbation for stroke patients that do not achieve vascular recanalization with rtPA.


Subject(s)
Cerebral Infarction/complications , Stroke/complications , Thrombolytic Therapy/adverse effects , Tissue Plasminogen Activator/adverse effects , Animals , Animals, Genetically Modified , Blood-Brain Barrier/drug effects , Brain Edema/chemically induced , Brain Edema/complications , Cerebral Infarction/drug therapy , Data Interpretation, Statistical , Disease Models, Animal , Male , Rats , Recombinant Proteins/adverse effects , Recombinant Proteins/therapeutic use , Sensitivity and Specificity , Stroke/drug therapy , Tissue Plasminogen Activator/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...